Humanwell Healthcare Group Co Ltd banner

Humanwell Healthcare Group Co Ltd
SSE:600079

Watchlist Manager
Humanwell Healthcare Group Co Ltd Logo
Humanwell Healthcare Group Co Ltd
SSE:600079
Watchlist
Price: 18.71 CNY -0.48% Market Closed
Market Cap: ¥30.5B

EV/EBIT

9.6
Current
28%
Cheaper
vs 3-y average of 13.2

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
9.6
=
Enterprise Value
¥35.5B
/
EBIT
¥3.7B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
9.6
=
Enterprise Value
¥35.5B
/
EBIT
¥3.7B

Valuation Scenarios

Humanwell Healthcare Group Co Ltd is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (13.2), the stock would be worth ¥25.86 (38% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+202%
Average Upside
107%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 9.6 ¥18.71
0%
3-Year Average 13.2 ¥25.86
+38%
5-Year Average 13.7 ¥26.66
+42%
Industry Average 23.4 ¥45.78
+145%
Country Average 28.9 ¥56.43
+202%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
¥35.5B
/
Jan 2026
¥3.7B
=
9.6
Current
¥35.5B
/
Dec 2026
¥4.2B
=
8.5
Forward
¥35.5B
/
Dec 2027
¥4.7B
=
7.6
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
CN
Humanwell Healthcare Group Co Ltd
SSE:600079
30.5B CNY 9.6 16.5
US
Eli Lilly and Co
NYSE:LLY
869.1B USD 30.4 42.1
US
Johnson & Johnson
NYSE:JNJ
555.5B USD 21.7 26.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.2 19.8
UK
AstraZeneca PLC
LSE:AZN
231.9B GBP 23.2 29.8
US
Merck & Co Inc
NYSE:MRK
289.8B USD 12 15.9
CH
Novartis AG
SIX:NOVN
228B CHF 16.1 20.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 970 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 9.7 11.2
US
Pfizer Inc
NYSE:PFE
156.5B USD 10.3 20.1
US
Bristol-Myers Squibb Co
NYSE:BMY
119B USD 8.8 16.9
P/E Multiple
Earnings Growth PEG
CN
Humanwell Healthcare Group Co Ltd
SSE:600079
Average P/E: 21.9
16.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.1
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.4
8%
3.3
CH
Roche Holding AG
SIX:ROG
19.8
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.8
25%
1.2
US
Merck & Co Inc
NYSE:MRK
15.9
14%
1.1
CH
Novartis AG
SIX:NOVN
20.2
14%
1.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
0%
N/A
US
Pfizer Inc
NYSE:PFE
20.1
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.9
16%
1.1

Market Distribution

Lower than 85% of companies in China
Percentile
15th
Based on 5 337 companies
15th percentile
9.6
Low
0 — 16.6
Typical Range
16.6 — 52.9
High
52.9 —
Distribution Statistics
China
Min 0
30th Percentile 16.6
Median 28.9
70th Percentile 52.9
Max 49 021

Humanwell Healthcare Group Co Ltd
Glance View

Market Cap
30.5B CNY
Industry
Pharmaceuticals

In the rapidly evolving landscape of the Chinese pharmaceutical industry, Humanwell Healthcare Group Co Ltd. stands as a multifaceted player with its roots deeply embedded in both innovation and tradition. Founded in Wuhan, Humanwell has cultivated a robust portfolio that extends beyond the manufacture and distribution of pharmaceuticals, marking its presence in fields like anesthetics, reproductive health products, and specialty chemicals. Anchoring its operations is a commitment to research and development, investing significantly in new technologies and drug formulations. Humanwell leverages its extensive manufacturing capabilities and adheres to rigorous quality controls, enabling it to efficiently produce and market a diverse array of products across domestic and international markets. The company’s financial structure is bolstered by a savvy integration of its capabilities and strategic partnerships, enhancing both its market reach and product offerings. With subsidiaries spread across different continents, Humanwell taps into the lucrative supply chains of the healthcare sector, accentuating its revenue streams. Through strategic acquisitions and partnerships, the company has invested in expanding its global footprint, enhancing its competitive prowess. This tactical expansion, coupled with a keen focus on understanding and fulfilling consumer needs, allows Humanwell Healthcare not only to sustain a strong financial performance but also to play a pivotal role in shaping the future of the healthcare market in China and beyond.

Intrinsic Value
30.38 CNY
Undervaluation 38%
Intrinsic Value
Price ¥18.71
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett